Citation

Wernicke JF. Expert Opin. Drug Saf. 2004; 3(5): 495-504.

Affiliation

Lilly Corporate Center, Indianapolis, IN 46285, USA. jfwernicke@lilly.com

Copyright

(Copyright © 2004, Informa Healthcare)

DOI

10.1517/14740338.3.5.495

PMID

15335304

Abstract

Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders. Its attributes have been described in numerous scientific papers, and it has been the subject of a considerable volume of lay press. Fluoxetine is generally safe and well-tolerated. Common adverse events reported with the recommended dose of 20 mg/day are referable to the gastrointestinal system and the nervous system. The approved dose range is up to 80 mg/day, and when higher doses are used, adverse events are more common. The long half-life of fluoxetine and its active metabolite essentially preclude a withdrawal phenomenon. It is an inhibitor of cytochrome P450 (CYP) 2D6 and other CYP enzymes, which increases the potential for drug interactions. However, most of these are not clinically important. The purpose of this review is to provide an overview of some of the most important information related to safety and side effects of this drug.

Language: en